Question special
Lead Moderator

The concept of targeted gene therapy has led to much promise in the treatment of cancer based on genotype. Methods for assaying specimens comprehensively and cost-effectively will undoubtedly be an important step towards this paradigm shift in treatment. I was wondering if Dr. Pritchard, who together with colleagues developed a clinical molecular diagnostic assay for this aim, could speak more on this topic, particularly as it pertains to the promise and future use of such tools. I invite our other panelists to comment as well!